ETF DAILY NEWS
Akebia Therapeutics (NASDAQ:AKBA) Rating Lowered to Hold at StockNews.com
Separately, HC Wainwright boosted their price target on shares of Akebia Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Thursday, March 28th. 7 Stocks to Buy ...
2 days ago
FOX 59 Indianapolis
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 10 newly-hired employees options to purchase ...
1 day ago
Simply Wall St. via Yahoo
When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
4 days ago
Knox Daily
Akebia Therapeutics Inc. [AKBA] Stock sold by Insider Butler John P. for $73581.0 – Knox Daily
A total of 1.82 million shares were traded, compared to the trading of 1.54 million shares in the previous session. Levels Of Support And Resistance For AKBA Stock The 24-hour chart illustrates ...
3 days ago
View all
akebia.com
More on Yahoo Finance